Strategic expansion Recent facility expansions in India and Bangalore signal increased manufacturing capacity and readiness for larger-scale biologics production, presenting opportunities to offer end-to-end CDMO services from development through commercial manufacturing.

Collaborative partnerships Active collaboration with Renaissance Pharma on FDA Fast Track mAb programs indicates a receptiveness to co-development and manufacturing alliances, suggesting potential for joint development, tech transfer, and scalable manufacturing engagements.

Innovative platforms Launch of CHOMax cell line development and manufacturing platform demonstrates a capability to accelerate DNA to IND-enabling supply for IgG mAbs, offering sales angles around faster timelines, risk reduction, and integrated biologics workflows.

Biologics capability GMP biologics manufacturing expansion and readiness to commence late-stage production imply a strong fit for customers seeking scalable biologics manufacture, including clinical to commercial transition services.

Strategic investments Significant funding activity and a high-growth revenue profile position Aragen as a credible partner for large-scale CRO/CMO collaborations, enabling conversations around long-term programs, capacity planning, and global delivery.